A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Sotagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms inTandem3
  • Sponsors Lexicon Pharmaceuticals; Sanofi
  • Most Recent Events

    • 13 Sep 2017 Results published in the New England Journal of Medicine
    • 13 Sep 2017 According to a Lexicon Pharmaceuticals media release, data were presented at European Association for the Study of Diabetes (EASD) 53rd annual meeting and published in the New England Journal of Medicine (NEJM).
    • 13 Sep 2017 Results published in a Lexicon Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top